Why Pharma and MedTech Must Modernize Quality by 2026 focuses on the growing urgency for quality system modernization across regulated life sciences industries. The episode explores why legacy quality frameworks are no longer sufficient in an environment defined by increased regulatory scrutiny, complex global supply chains, and rapidly advancing technologies.
The conversation breaks down what modernization really means in practice, from digitizing quality processes and strengthening data integrity to adopting risk-based approaches that align with current FDA expectations. This episode emphasizes that quality modernization is not just a compliance exercise, but a strategic necessity for organizations looking to remain competitive, inspection-ready, and resilient as regulatory expectations continue to evolve.
